Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales. Dupilumab (Dupixent®) is licensed for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. Dupilumab (Dupixent®) is restricted for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy and where existing systemic therapies are not advisable. Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | dupilumab (Dupixent®) | ||
| Formulation | 200 mg and 300 mg solution for injection | ||
| Reference number | 3858 | ||
| Indication | Treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy |
||
| Company | Sanofi | ||
| BNF chapter | Skin | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 0221 | ||
| NMG meeting date | 06/01/2021 | ||
| AWMSG meeting date | 09/02/2021 | ||
| Date of issue | 17/03/2021 | ||
| Commercial arrangement | PAS | ||